Browsing Tag
LAG-3 immunotherapy
2 posts
Why Immutep Limited halted its lung cancer trial and how the decision reshapes its immunotherapy strategy (NASDAQ: IMMP)
Immutep Limited halts the TACTI-004 Phase III lung cancer trial. Discover what the futility result means for eftilagimod alfa and LAG-3 immunotherapy.
Immutep (ASX: IMM) closing in on critical readout — biotech traders discuss risk vs reward heading into 2026
Immutep Limited surpasses 170 patients in its global Phase III NSCLC trial, setting up a 2026 futility readout that could redefine its immunotherapy pipeline.